Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients

American Journal of Kidney Diseases

Volumn 58, Issue 1, 2011, Pages 73-83

  Wetmore, James B ^a,d   Mahnken, Jonathan D ^a   Mukhopadhyay, Purna ^a   Hou, Qingjiang ^a   Ellerbeck, Edward F ^a   Rigler, Sally K ^a   Spertus, John A ^b,c   Shireman, Theresa I ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d Division of Nephrology   (United States)

Author keywords

Antihypertensive drugs; cardioprotection; dialysis; end stage renal disease; insurance; Medicaid; Medicare

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRESCRIPTION DRUG;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; FUNCTIONAL STATUS; GEOGRAPHIC DISTRIBUTION; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CROSS-SECTIONAL STUDIES; FEMALE; HEART DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICAID; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 79959363488     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.02.387     Document Type: Article

References (62)

1. A.A. Lopes, J.L. Bragg-Gresham, and S.P. Ramirez Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS Nephrol Dial Transplant 24 9 2009 2809 2816
2. R.O. Estacio, B.W. Jeffers, W.R. Hiatt, S.L. Biggerstaff, N. Gifford, and R.W. Schrier The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 338 10 1998 645 652 (Pubitemid 28108434)
3. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 9169 1999 2001 2007
4. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 3 2000 145 153
5. H.J. Dargie Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 9266 2001 1385 1390 (Pubitemid 32455364)
6. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
7. S.E. Kjeldsen, B. Dahlof, and R.B. Devereux Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy JAMA 288 12 2002 1491 1498
8. P.A. Poole-Wilson, K. Swedberg, and J.G. Cleland Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 9377 2003 7 13 (Pubitemid 36835815)
9. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 9386 2003 767 771 (Pubitemid 37093916)
10. M.A. Pfeffer, J.J. McMurray, and E.J. Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 20 2003 1893 1906 (Pubitemid 37409706)
11. S. Wassertheil-Smoller, B. Psaty, and P. Greenland Association between cardiovascular outcomes and antihypertensive drug treatment in older women JAMA 292 23 2004 2849 2859 (Pubitemid 39628232)
12. C. Demers, J.J. McMurray, and K. Swedberg Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure JAMA 294 14 2005 1794 1798 (Pubitemid 41435112)
13. B. Dahlof, P.S. Sever, and N.R. Poulter Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 9489 2005 895 906 (Pubitemid 41265663)
14. K. Jamerson, M.A. Weber, and G.L. Bakris Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 23 2008 2417 2428
15. I.K. Mohan, M. Khan, and S. Wisel Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction Am J Physiol Heart Circ Physiol 296 1 2009 H140 H151
16. L.A. Ahmed, H.A. Salem, A.S. Attia, and M.E. El-Sayed Enhancement of amlodipine cardioprotection by quercetin in ischaemia/reperfusion injury in rats J Pharm Pharmacol 61 9 2009 1233 1241
17. R.N. Foley, C.A. Herzog, and A.J. Collins Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study Kidney Int 62 5 2002 1784 1790 (Pubitemid 35286287)
18. A. Ishani, C.A. Herzog, A.J. Collins, and R.N. Foley Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Kidney Int 65 3 2004 1017 1025 (Pubitemid 38251078)
19. T.F. Griffith, B.S. Chua, A.S. Allen, P.S. Klassen, D.N. Reddan, and L.A. Szczech Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients Am J Kidney Dis 42 6 2003 1260 1269 (Pubitemid 37486771)
20. K.C. Abbott, F.C. Trespalacios, L.Y. Agodoa, A.J. Taylor, and G.L. Bakris Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality Arch Intern Med 164 22 2004 2465 2471 (Pubitemid 39628074)
21. B. Kestenbaum, D.L. Gillen, D.J. Sherrard, S. Seliger, A. Ball, and C. Stehman-Breen Calcium channel blocker use and mortality among patients with end-stage renal disease Kidney Int 61 6 2002 2157 2164 (Pubitemid 34539333)
22. US Renal Data System USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2003 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
23. US Renal Data System USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2006 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
24. J.B. Wetmore, S.K. Rigler, J.D. Mahnken, P. Mukhopadhyay, and T.I. Shireman Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage? Nephrol Dial Transplant. 25 1 2010 198 205
25. J.G. Douglas, G.L. Bakris, and M. Epstein Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med 163 5 2003 525 541 (Pubitemid 36314340)
26. C.D. Furberg, B.M. Psaty, and J.V. Meyer Nifedipine Dose-related increase in mortality in patients with coronary heart disease Circulation 92 5 1995 1326 1331
27. C. McCulloch, and S. Searle Generalized Linear Mixed Models (GLMMs) Generalized, Linear, and Mixed Models 2001 John Wiley & Sons Inc New York, NY 220 245 Ch. 8
28. D.W. Hosmer, and S. Lemeshow Applied Logistic Regression 2nd ed. 2000 John Wiley & Sons Inc New York, NY
29. R.C. Littell, G.A. Milliken, W.W. Stroup, R.D. Wolfinger, and O. Schabenberger SAS® for Mixed Models 2nd ed 2006 SAS Institute Inc Cary, NC 745
30. National Pharmaceutical Council Pharmaceutical Benefits Under State Medical Assistance Programs http://www.npcnow.org/Public/Research-Publications/ Publications/pub-rel-research/pub-medicaid/Pharmaceutical-Benefits-Under-State- Medical-Assistance-Programs-2005.aspx Accessed December 7, 2010
31. J.B. Wetmore, and T.I. Shireman The ABCs of cardioprotection in dialysis patients: a systematic review Am J Kidney Dis 53 3 2009 457 466
32. G. Cice, L. Ferrara, and A. D'Andrea Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial J Am Coll Cardiol 41 9 2003 1438 1444 (Pubitemid 36543357)
33. F. Zannad, M. Kessler, and P. Lehert Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 7 2006 1318 1324 (Pubitemid 44435184)
34. S. Efrati, R. Zaidenstein, and V. Dishy ACE inhibitors and survival of hemodialysis patients Am J Kidney Dis 40 5 2002 1023 1029 (Pubitemid 35265483)
35. P.A. McCullough, K.R. Sandberg, S. Borzak, M.P. Hudson, M. Garg, and H.J. Manley Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease Am Heart J 144 2 2002 226 232 (Pubitemid 34879643)
36. A.K. Berger, S. Duval, and H.M. Krumholz Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction J Am Coll Cardiol 42 2 2003 201 208 (Pubitemid 36851405)
37. W.C. Winkelmayer, D.M. Charytan, R. Levin, and J. Avorn Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction Am J Kidney Dis 47 2 2006 301 308 (Pubitemid 43121333)
38. I.H. de Boer, G.N. Ioannou, B. Kestenbaum, J.D. Brunzell, and N.S. Weiss 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III) Am J Kidney Dis 50 1 2007 69 77 (Pubitemid 46962855)
39. F.C. Trespalacios, A.J. Taylor, L.Y. Agodoa, and K.C. Abbott Incident acute coronary syndromes in chronic dialysis patients in the United States Kidney Int 62 5 2002 1799 1805 (Pubitemid 35286289)
40. F.Y. Chow, K.R. Polkinghorne, S.J. Chadban, R.C. Atkins, and P.G. Kerr Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001 Nephrology (Carlton) 8 4 2003 177 183 (Pubitemid 36995087)
41. C.A. Boger, A.K. Gotz, and B. Kruger Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients Eur J Med Res 10 4 2005 161 168 (Pubitemid 40584986)
42. M. Tepel, M.V. Giet, A. Park, and W. Zidek Association of calcium channel blockers and mortality in haemodialysis patients Clin Sci (Lond) 103 5 2002 511 515 (Pubitemid 35305636)
43. S. Hopson, D. Frankenfield, M. Rocco, and W. McClellan Variability in reasons for hemodialysis catheter use by race, sex, and geography: findings from the ESRD Clinical Performance Measures Project Am J Kidney Dis 52 4 2008 753 760
44. R.N. Foley, S.C. Chen, and A.J. Collins Hemodialysis access at initiation in the United States, 2005 to 2007: still "catheter first." Hemodial Int 13 4 2009 533 542
45. V.B. Ashby, J.D. Kalbfleisch, R.A. Wolfe, M.J. Lin, F.K. Port, and A.B. Leichtman Geographic variability in access to primary kidney transplantation in the United States, 1996-2005 Am J Transplant 7 5, pt 2 2007 1412 1423 (Pubitemid 46606944)
46. A.M. O'Hare, R.A. Dudley, and D.M. Hynes Impact of surgeon and surgical center characteristics on choice of permanent vascular access Kidney Int 64 2 2003 681 689 (Pubitemid 36871942)
47. W.M. McClellan, H. Wasse, A.C. McClellan, A. Kipp, L.A. Waller, and M.V. Rocco Treatment center and geographic variability in pre-ESRD care associate with increased mortality J Am Soc Nephrol 20 5 2009 1078 1085
48. M.M. Sood, M. Battistella, and C.E. Lok Patterns of cardioprotective medication prescription in incident hemodialysis patients Int Urol Nephrol 41 4 2009 1021 1027
49. M. Wong, L. Staszewsky, and R. Latini Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study J Am Coll Cardiol 40 5 2002 970 975 (Pubitemid 34994994)
50. B. Greenberg, M.A. Quinones, and C. Koilpillai Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction Results of the SOLVD echocardiography substudy Circulation 91 10 1995 2573 2581
51. M. Jessup, and S. Brozena Heart failure N Engl J Med 348 20 2003 2007 2018
52. G. Malfatto, M. Facchini, G. Branzi, B. Riva, L. Sala, and G.B. Perego Long-term treatment with the beta-blocker carvedilol restores autonomic tone and responsiveness in patients with moderate heart failure J Cardiovasc Pharmacol 42 1 2003 125 131 (Pubitemid 36791360)
53. S.C. Smith Jr, J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute J Am Coll Cardiol 47 10 2006 2130 2139 (Pubitemid 44275145)
54. E.R. Mohler III Peripheral arterial disease: identification and implications Arch Intern Med 163 19 2003 2306 2314
55. A.T. Hirsch, Z.J. Haskal, and N.R. Hertzer ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation Circulation 113 11 2006 e463 e654
56. S.S. DeLoach, and E.R. Mohler III Peripheral arterial disease: a guide for nephrologists Clin J Am Soc Nephrol 2 4 2007 839 846
57. H.J. Manley, C.G. Garvin, and D.K. Drayer Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider Nephrol Dial Transplant 19 7 2004 1842 1848 (Pubitemid 38961397)
58. US Renal Data System USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2005 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
59. P.W. Eggers CMS 2728: what good is it? Clin J Am Soc Nephrol. 5 11 2010 1908 1909
60. How good are the data? USRDS data validation special study Am J Kidney Dis. 20 5(suppl 2 1992 68 83
61. B. Glintborg, H.E. Poulsen, and K.P. Dalhoff The use of nationwide on-line prescription records improves the drug history in hospitalized patients Br J Clin Pharmacol 65 2 2008 265 269 (Pubitemid 351171273)
62. T.L. Warholak, M. McCulloch, A. Baumgart, M. Smith, W. Fink, and W. Fritz An exploratory comparison of medication lists at hospital admission with administrative database records J Manag Care Pharm 15 9 2009 751 758